189 related articles for article (PubMed ID: 26637705)
1. B-cell receptor pathway modulators in NHL.
Blum KA
Hematology Am Soc Hematol Educ Program; 2015; 2015():82-91. PubMed ID: 26637705
[TBL] [Abstract][Full Text] [Related]
2. Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
Rodgers TD; Reagan PM
Expert Opin Emerg Drugs; 2018 Jun; 23(2):111-122. PubMed ID: 29781323
[TBL] [Abstract][Full Text] [Related]
3. Targeting of B-cell receptor signalling in B-cell malignancies.
Jerkeman M; Hallek M; Dreyling M; Thieblemont C; Kimby E; Staudt L
J Intern Med; 2017 Nov; 282(5):415-428. PubMed ID: 28295729
[TBL] [Abstract][Full Text] [Related]
4. Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110
Alfaro J; Pérez de Arce F; Belmar S; Fuentealba G; Avila P; Ureta G; Flores C; Acuña C; Delgado L; Gaete D; Pujala B; Barde A; Nayak AK; Upendra TVR; Patel D; Chauhan S; Sharma VK; Kanno S; Almirez RG; Hung DT; Chakravarty S; Rai R; Bernales S; Quinn KP; Pham SM; McCullagh E
J Pharmacol Exp Ther; 2017 May; 361(2):312-321. PubMed ID: 28298527
[TBL] [Abstract][Full Text] [Related]
5. Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
Valla K; Flowers CR; Koff JL
Expert Opin Investig Drugs; 2018 Jun; 27(6):513-522. PubMed ID: 29855199
[TBL] [Abstract][Full Text] [Related]
6. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
8. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
Moyo TK; Wilson CS; Moore DJ; Eischen CM
Oncogene; 2017 Aug; 36(32):4653-4661. PubMed ID: 28368423
[TBL] [Abstract][Full Text] [Related]
9. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
10. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
11. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
Hill RJ; Lou Y; Tan SL
Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
[TBL] [Abstract][Full Text] [Related]
12. Membrane-associated signaling in human B-lymphoma lines.
Tauzin S; Ding H; Burdevet D; Borisch B; Hoessli DC
Exp Cell Res; 2011 Jan; 317(2):151-62. PubMed ID: 20875408
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.
Choi MY; Kipps TJ
Cancer J; 2012; 18(5):404-10. PubMed ID: 23006944
[TBL] [Abstract][Full Text] [Related]
14. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
Davids MS; Brown JR
Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
[TBL] [Abstract][Full Text] [Related]
15. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders.
Castillo JJ; Treon SP; Davids MS
Cancer J; 2016; 22(1):34-9. PubMed ID: 26841015
[TBL] [Abstract][Full Text] [Related]
17. Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathway.
Zoellner AK; Bayerl S; Hutter G; Zimmermann Y; Hiddemann W; Dreyling M
Leuk Lymphoma; 2015; 56(12):3393-400. PubMed ID: 26237681
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase.
Buhl AM; Cambier JC
J Immunol; 1999 Apr; 162(8):4438-46. PubMed ID: 10201980
[TBL] [Abstract][Full Text] [Related]
19. The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways.
Kenkre VP; Kahl BS
Curr Hematol Malig Rep; 2012 Sep; 7(3):216-20. PubMed ID: 22688757
[TBL] [Abstract][Full Text] [Related]
20. Targeting indolent non-Hodgkin lymphoma.
Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
